233 related articles for article (PubMed ID: 35439056)
1. Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins.
Mukherjee S; Maddalena M; Lü Y; Martinez S; Nataraj NB; Noronha A; Sinha S; Teng K; Cohen-Kaplan V; Ziv T; Arandkar S; Hassin O; Chatterjee R; Pirona AC; Shreberk-Shaked M; Gershoni A; Aylon Y; Elazar Z; Yarden Y; Schramek D; Oren M
Proc Natl Acad Sci U S A; 2022 Apr; 119(17):e2119644119. PubMed ID: 35439056
[TBL] [Abstract][Full Text] [Related]
2. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14.
Du Y; Liu Z; You L; Hou P; Ren X; Jiao T; Zhao W; Li Z; Shu H; Liu C; Zhao Y
Cancer Res; 2017 May; 77(10):2661-2673. PubMed ID: 28280038
[TBL] [Abstract][Full Text] [Related]
4. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
5. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
Front Oncol; 2021; 11():642603. PubMed ID: 34178628
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion.
Coffill CR; Muller PA; Oh HK; Neo SP; Hogue KA; Cheok CF; Vousden KH; Lane DP; Blackstock WP; Gunaratne J
EMBO Rep; 2012 Jun; 13(7):638-44. PubMed ID: 22653443
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract][Full Text] [Related]
8. Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles.
Zhang H; Zhang W; Hu B; Qin X; Yi T; Ye Y; Huang X; Song Y; Yang Z; Qian J; Zhang Y
J Nanobiotechnology; 2023 Apr; 21(1):117. PubMed ID: 37005668
[TBL] [Abstract][Full Text] [Related]
9. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
10. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
Elife; 2015 Aug; 4():. PubMed ID: 26271008
[TBL] [Abstract][Full Text] [Related]
11. Proteasomal and autophagy-mediated degradation of mutp53 proteins through mitochondria-targeting aggregation-induced-emission materials.
Wang M; Yang Z; Song Y; Wei P; Ishiwme N; Wang L; Zhang H; Jing M; Gao M; Wen L; Zhang Y
Acta Biomater; 2022 Sep; 150():402-412. PubMed ID: 35931280
[TBL] [Abstract][Full Text] [Related]
12.
Maddalena M; Mallel G; Nataraj NB; Shreberk-Shaked M; Hassin O; Mukherjee S; Arandkar S; Rotkopf R; Kapsack A; Lambiase G; Pellegrino B; Ben-Isaac E; Golani O; Addadi Y; Hajaj E; Eilam R; Straussman R; Yarden Y; Lotem M; Oren M
Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34088837
[TBL] [Abstract][Full Text] [Related]
13. Tumour-associated mutant p53 drives the Warburg effect.
Zhang C; Liu J; Liang Y; Wu R; Zhao Y; Hong X; Lin M; Yu H; Liu L; Levine AJ; Hu W; Feng Z
Nat Commun; 2013; 4():2935. PubMed ID: 24343302
[TBL] [Abstract][Full Text] [Related]
14. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
15. Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.
Zheng T; Wang J; Zhao Y; Zhang C; Lin M; Wang X; Yu H; Liu L; Feng Z; Hu W
Nat Commun; 2013; 4():2996. PubMed ID: 24356649
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 Gain-of-Function Induces Migration and Invasion through Overexpression of miR-182-5p in Cancer Cells.
Madrigal T; Ortega-Bernal D; Herrera LA; González-De la Rosa CH; Domínguez-Gómez G; Aréchaga-Ocampo E; Díaz-Chávez J
Cells; 2023 Oct; 12(20):. PubMed ID: 37887350
[TBL] [Abstract][Full Text] [Related]
17.
Pan M; Jiang C; Zhang Z; Achacoso N; Alexeeff S; Solorzano AV; Tse P; Chung E; Sundaresan T; Suga JM; Thomas S; Habel LA
JCO Precis Oncol; 2023 May; 7():e2200570. PubMed ID: 37163715
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib Nanomicelles Synergize with Chemotherapy through Inducing Proteasomal Degradation of Mutp53 Proteins.
Yi T; Qian J; Ye Y; Zhang H; Jin X; Wang M; Yang Z; Zhang W; Wen L; Zhang Y
ACS Appl Mater Interfaces; 2023 Jan; 15(1):511-523. PubMed ID: 36578131
[TBL] [Abstract][Full Text] [Related]
19. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
